GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets
GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic…
MORERelated News
Introducing Fierce Biotech’s 2024 Fierce 15 – OMass Therapeutics
August 5, 2024
What makes OMass fierce: You can’t fault OMass for its ambition. The company may still be in preclinical development, but it...
Dame Carol Robinson to receive Lifetime Achievement Award for groundbreaking protein analysis work
June 25, 2024
The European Patent Office (EPO) has announced that Dame Carol Robinson, Professor of Chemistry at the University of Oxford, will receive...
5 Pharmaceutical Companies in the UK to Know
March 11, 2024
OMass uses high-resolution mass spectrometry to study protein assemblies and discover new medicines. Its spectrometry platform, called OdyssION, enables better visualization...
